Novel recombinant lysin and its use in the treatment of Gram-negative bacterial infections
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- テラム セラピューティクス エセエレ
- Filing Date
- 2021-03-11
- Publication Date
- 2026-05-21
AI Technical Summary
There is a need for novel lysinogens with improved properties to effectively eradicate multidrug-resistant (MDR) Gram-negative bacteria, particularly Escherichia coli, while minimizing the development of resistance, and to provide safe and selective treatment options for infections caused by bacteria such as Klebsiella pneumoniae and Pseudomonas aeruginosa.
A novel recombinant endolysin comprising a domain with peptidoglycan hydrolase activity and a cell permeability domain is developed, enhancing the permeability of the outer membrane of Gram-negative bacteria, thereby achieving high bactericidal efficacy against E. coli, K. pneumoniae, and P. aeruginosa without affecting Gram-positive bacteria or the host microbiome.
The recombinant endolysin demonstrates superior bactericidal activity against MDR strains of E. coli, K. pneumoniae, and P. aeruginosa at lower concentrations and shorter incubation times compared to existing chimeric proteins, with no toxicity to mammalian cells and minimal impact on the gut microbiota, and shows synergistic effects with antibiotics.
Smart Images
Figure 0007863509000005 
Figure 0007863509000006 
Figure 0007863509000007